Skip to main content
SpringerLink
Log in

Hepatitis B and C Viruses

  • Chapter
Molecular Pathology in Clinical Practice

  • 3549 Accesses

Abstract

Hepatitis due to infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are major global public health problems. Molecular diagnostic methods are now standard of care for the diagnosis, management and monitoring therapy of patients with chronic hepatitis B and C. After a brief description of the viruses and clinical manifestations of infection, the clinical utility of viral load testing and genotyping for HBV and HCV are reviewed. The relative advantages and limitations of the commercially available methods for performing these tests will be compared and key laboratory issues affecting the results are highlighted. The chapter also provides guidance for interpretation of these test results and insight into future directions for molecular diagnostic testing in patients with hepatitis B and C.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Blumberg BS, Alter HJ, Visnich S. A “New” antigen in leukemia sera. JAMA. 1965;191:541–6.

    Article  CAS  PubMed  Google Scholar 

  2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62.

    Article  CAS  PubMed  Google Scholar 

  3. Horvath R, Tegtmeier GE. Hepatitis B and D viruses. In: Versalovic J et al., editors. Manual of clinical microbiology. 10th ed. Washington, DC: ASM Press; 2011.

    Google Scholar 

  4. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown Jr RS, Luketic VA, Terrault N, Lok AS. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003;125:444–51.

    Article  PubMed  Google Scholar 

  5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

    Article  PubMed  Google Scholar 

  6. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther. 2006;10:77–91.

    Article  CAS  PubMed  Google Scholar 

  7. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–9.

    Article  CAS  PubMed  Google Scholar 

  8. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology. 1997;26:786–91.

    Article  CAS  PubMed  Google Scholar 

  9. McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, Nadler PI, Ostberg L. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology. 1992;15:757–66.

    Article  CAS  PubMed  Google Scholar 

  10. Hillyard DR. Molecular detection and characterization of hepatitis B virus. In: Persing DH et al., editors. Molecular microbiology: diagnostic principles and practice, vol. 2. 2nd ed. Washington, DC: ASM Press; 2011. p. 579.

    Chapter  Google Scholar 

  11. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 1994;68:8102–10.

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588–91.

    Article  CAS  PubMed  Google Scholar 

  13. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat. 1997;4:1–8.

    Article  CAS  PubMed  Google Scholar 

  14. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology. 2009;49:S129–37.

    Article  PubMed  Google Scholar 

  15. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology. 2009;49:S166–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Hussain M, Chu CJ, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol. 2003;41:3699–705.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Osiowy C, Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J Clin Microbiol. 2003;41:5473–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–41.

    Article  CAS  PubMed  Google Scholar 

  19. Chu CJ, Lok AS. Clinical utility in quantifying serum HBV DNA levels using PCR assays. J Hepatol. 2002;36:549–51.

    Article  CAS  PubMed  Google Scholar 

  20. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408–15.

    Article  CAS  PubMed  Google Scholar 

  21. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703–12.

    Article  CAS  PubMed  Google Scholar 

  22. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 2001;80:63–71.

    Article  CAS  PubMed  Google Scholar 

  23. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83:1718–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88:2451–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Okamoto H, Kurai K, Okada S, Yamamoto K, Lizuka H, Tanaka T, Fukuda S, Tsuda F, Mishiro S. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology. 1992;188:331–41.

    Article  CAS  PubMed  Google Scholar 

  27. Smith DB, Bukh J, Kuiken C, Muerhoff S, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–27.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994;19:13–8.

    Article  CAS  PubMed  Google Scholar 

  29. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74:2391–9.

    Article  CAS  PubMed  Google Scholar 

  30. Murphy DG, Willems B, Deschênes M, Hilzenat N, Mousseau R, Sabbah S. Use of sequence analysis with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol. 2007;45:1102–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology. 1997;25:211–5.

    Article  CAS  PubMed  Google Scholar 

  32. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.

    Article  CAS  PubMed  Google Scholar 

  33. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1–39.

    Google Scholar 

  34. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

    Article  CAS  PubMed  Google Scholar 

  35. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050–68.

    CAS  PubMed  Google Scholar 

  36. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(1-13):15.

    Google Scholar 

  37. Centers for Disease Control and Prevention. Testing for HCV infection: an update of Guidance for Clinicians and Laboratorians. MMWR Recomm Rep. 2013;62:362–5.

    Google Scholar 

  38. Fanning L, Kenny-Walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, Whelton M, Shanahan F. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology. 2000;31:225–9.

    Article  CAS  PubMed  Google Scholar 

  39. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685–90.

    Article  CAS  PubMed  Google Scholar 

  40. Legler TJ, Riggert J, Simson G, Wolf C, Humpe A, Munzel U, Uy A, Kohler M, Heermann KH. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion. 2000;40:1192–7.

    Article  CAS  PubMed  Google Scholar 

  41. Kolk DP, Dockter J, Linnen J, Ho-Sing-Loy M, Gillotte-Taylor K, McDonough SH, Mimms L, Giachetti C. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol. 2002;40:1761–6.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, Crovari P. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol. 2001;39:3110–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36:211–8.

    Article  CAS  PubMed  Google Scholar 

  44. Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol. 2003;41:3212–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol. 2009;46:210–5.

    Article  CAS  PubMed  Google Scholar 

  46. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods. 2009;157:8–14.

    Article  CAS  PubMed  Google Scholar 

  47. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–92.

    Article  CAS  PubMed  Google Scholar 

  48. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–32.

    Article  CAS  PubMed  Google Scholar 

  49. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(120-129):e118.

    Google Scholar 

  50. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821–7. 827.e821.

    Article  CAS  PubMed  Google Scholar 

  51. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol. 1996;91:1516–22.

    CAS  PubMed  Google Scholar 

  52. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanien T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al. Sofosbuvir for previously untreated chronic hepatitis C. N Engl J Med. 2013;368:1878–87.

    Article  CAS  PubMed  Google Scholar 

  54. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nitkin I, Poordad F, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 Hepatitic C: the randomized PILLAR study. Hepatology. 2013;58:1918–29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Hohne M, Schreier E, Roggendorf M. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch Virol. 1994;137:25–34.

    Article  CAS  PubMed  Google Scholar 

  56. Power JP, Lawlor E, Davidson F, Holmes EC, Yap PL, Simmonds P. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet. 1995;345:1211–3.

    Article  CAS  PubMed  Google Scholar 

  57. Bronowicki JP, Venard V, Botte C, Monhoven N, Gastin I, Chone L, Hudziak H, Rihn B, Delanoe C, LeFaou A, Bigard MA, Gaucher P. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med. 1997;337:237–40.

    Article  CAS  PubMed  Google Scholar 

  58. Aizaki H, Saito A, Kusakawa I, Ashiwara Y, Nagamori S, Toda G, Suzuki T, Ishii K, Matsuura Y, Miyamura T. Mother-to-child transmission of a hepatitis C virus variant with an insertional mutation in its hypervariable region. J Hepatol. 1996;25:608–13.

    Article  CAS  PubMed  Google Scholar 

  59. Chayama K, Kobayashi M, Tsubota A, Koida I, Arase Y, Saitoh S, Ikeda K, Kumada H. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol. 1995;22:431–9.

    Article  CAS  PubMed  Google Scholar 

  60. Healey CJ, Smith DB, Walker JL, Holmes EC, Fleming KA, Chapman RW, Simmonds P. Acute hepatitis C infection after sexual exposure. Gut. 1995;36:148–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Weiner AJ, Thaler MM, Crawford K, Ching K, Kansopon J, Chien DY, Hall JE, Hu F, Houghton M. A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J Virol. 1993;67:4365–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  62. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81.

    Article  CAS  PubMed  Google Scholar 

  63. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis. 2001;183:1195–203.

    Article  CAS  PubMed  Google Scholar 

  64. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers Jr RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol. 1997;53:118–26.

    Article  CAS  PubMed  Google Scholar 

  65. Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, Zeuzem S. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol. 1999;30:1004–13.

    Article  CAS  PubMed  Google Scholar 

  66. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–77.

    Article  CAS  PubMed  Google Scholar 

  67. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011;53:1742–51.

    Article  CAS  PubMed  Google Scholar 

  68. Olysio prescribing information. Janssen Therapeutics, Titusville, NJ. Reference ID 3412095, 2013

    Google Scholar 

  69. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.

    Article  CAS  PubMed  Google Scholar 

  70. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.

    Article  CAS  PubMed  Google Scholar 

  72. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.

    Article  CAS  PubMed  Google Scholar 

  73. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol. 2000;38:4171–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  74. Nolte FS, Fried MW, Shiffman ML, Ferreira-Gonzalez A, Garrett CT, Schiff ER, Polyak SJ, Gretch DR. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol. 2001;39:4005–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, Zitron I, Hendricks D, Gordon SC. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol. 2001;96:2968–72.

    Article  CAS  PubMed  Google Scholar 

  76. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology. 2000;32:818–23.

    Article  CAS  PubMed  Google Scholar 

  77. Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol. 2001;39:2850–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Krajden M, Ziermann R, Khan A, Mak A, Leung K, Hendricks D, Comanor L. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol. 2002;40:2903–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Jackson JB, Smith K, Knott C, Korpela A, Simmons A, Piwowar-Manning E, McDonough S, Mimms L, Vargo JM. Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol. 2002;40:2387–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, Boom R. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol. 2002;40:788–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Germer JJ, Heimgartner PJ, Ilstrup DM, Harmsen WS, Jenkins GD, Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol. 2002;40:495–500.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Caliendo AM, Valsamakis A, Zhou Y, Yen-Lieberman B, Andersen J, Young S, Ferreira-Gonzalez A, Tsongalis GJ, Pyles R, Bremer JW, Lurain NS. Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol. 2006;44:1726–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  83. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol. 2009;47:1726–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Germer JJ, Kathrotiya JD, Bouse CF, Mitchell PS, Yao JD. Anomalous quantitation standard growth curves in a laboratory-developed hepatitis C virus (HCV) RNA quantification assay using the TaqMan HCV analyte-specific reagent. J Clin Microbiol. 2009;47:2317–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol. 2009;47:2872–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Vermehren J, Colucci G, Gohl P, Hamdi N, Abdelaziz AI, Karey U, Thamke D, Zitzer H, Zeuzem S, Sarrazin C. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol. 2011;49:3309–15.

    Article  PubMed Central  PubMed  Google Scholar 

  87. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol. 2008;46:1901–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrere JJ, Pawlotsky JM, De Micco P, Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol. 2007;45:1140–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, Roggendorf M. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods. 1994;48:81–91.

    Article  CAS  PubMed  Google Scholar 

  90. Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, Roggendorf M. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol. 2000;38:3581–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  91. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995;15:41–63.

    Article  CAS  PubMed  Google Scholar 

  92. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol. 2002;76:4034–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Noppornpanth S, Lien TX, Poovorawan Y, Smits SL, Osterhaus AD, Haagmans BL. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol. 2006;80:7569–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Legrand-Abravanel F, Claudinon J, Nicot F, Dubois M, Chapuy-Regaud S, Sandres-Saune K, Pasquier C, Izopet J. New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol. 2007;81:4357–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Gao F, Nainan OV, Khudyakov Y, Li J, Hong Y, Gonzales AC, Spelbring J, Margolis HS. Recombinant hepatitis C virus in experimentally infected chimpanzees. J Gen Virol. 2007;88:143–7.

    Article  CAS  PubMed  Google Scholar 

  96. Sam SS, Steinmetz HB, Tsongalis GJ, Tafe LJ, Lefferts JA. Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. Exp Mol Pathol. 2013;95:18–22.

    Article  CAS  PubMed  Google Scholar 

  97. Hu YW, Balaskas E, Kessler G, Issid C, Scully LJ, Murphy DG, Rinfret A, Giulivi A, Scalia V, Gill P. Primer specific and mispair extension analysis (PSMEA) as a simple approach to fast genotyping. Nucleic Acids Res. 1998;26:5013–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  98. Krekulova L, Rehak V, Wakil AE, Harris E, Riley LW. Nested restriction site-specific PCR to detect and type hepatitis C virus (HCV): a rapid method to distinguish HCV subtype 1b from other genotypes. J Clin Microbiol. 2001;39:1774–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  99. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett EA, Seed CR, Krusius T, Lin C, Medgyesi GA, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol. 1995;76:1197–204.

    Article  CAS  PubMed  Google Scholar 

  100. White PA, Zhai X, Carter I, Zhao Y, Rawlinson WD. Simplified hepatitis C virus genotyping by heteroduplex mobility analysis. J Clin Microbiol. 2000;38:477–82.

    PubMed Central  CAS  PubMed  Google Scholar 

  101. Bullock GC, Bruns DE, Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem. 2002;48:2147–54.

    CAS  PubMed  Google Scholar 

  102. Schroter M, Zollner B, Schafer P, Landt O, Lass U, Laufs R, Feucht HH. Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes. J Clin Microbiol. 2002;40:2046–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  103. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol. 2001;8:200–6.

    Article  CAS  PubMed  Google Scholar 

  104. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490–5.

    Article  CAS  PubMed  Google Scholar 

  105. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 1995;9:1131–6.

    Article  CAS  PubMed  Google Scholar 

  106. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3–10.

    Article  PubMed  Google Scholar 

  107. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology. 2008;48:1412–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  108. Carlsson T, Quist A, Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol. 2008;80:803–7.

    Article  CAS  PubMed  Google Scholar 

  109. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang. 1999;76:149–58.

    Article  CAS  PubMed  Google Scholar 

  110. Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol. 2007;38:96–100.

    Article  CAS  PubMed  Google Scholar 

  111. Laperche S, Bouchardeau F, Thibault V, Pozzetto B, Vallet S, Rosenberg AR, Roque-Afonso AM, Gassin M, Stoll-Keller F, Trimoulet P, Gault E, Chanzy B, Mercier B, Branger M, Pawlotsky JM, Henquell C, Lunel F, Gaudy-Graffin C, Alain S, Chaix ML, Duverlie G, Izopet J, Lefrere JJ. Multicenter trials need to use the same assay for hepatitis C virus viral load determination. J Clin Microbiol. 2007;45:3788–90.

    Article  PubMed Central  PubMed  Google Scholar 

  112. Rice CM, Saeed M. Hepatitis C treatment triumphs. Nature. 2014;510:43–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Pathology, Pathology and Laboratory Medicine, Medical University of South Carolina, 171 Ashley Ave., MSC908, Charleston, SC, 29425-9080, USA

    Frederick S. Nolte Ph.D.

Authors
  1. Frederick S. Nolte Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederick S. Nolte Ph.D. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, University of Vermont College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA

    Debra G.B. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Nolte, F.S. (2016). Hepatitis B and C Viruses. In: Leonard, D. (eds) Molecular Pathology in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-19674-9_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19674-9_46

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19673-2

  • Online ISBN: 978-3-319-19674-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation